GlobeNewsWire
14 Aug 2026, 22:30 UTC · 2h ago
Avicanna Reports Q2 2026 Financial Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
GlobeNewsWire
14 Aug 2026, 22:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
4 claims · each scored for market impact
Avicanna is launching its proprietary QUIX™ rapid-onset portfolio in Q3 2026 with over 35 commercial listings already secured. — The transition from R&D to commercialization of a proprietary technology creates a new revenue stream and differentiates the company's product offering.
+0.60U.S. federal authorities have taken initial steps to reschedule certain cannabinoid-based products from Schedule I to Schedule III. — Rescheduling reduces regulatory barriers for pharmaceutical development and opens a path for the company to enter the massive U.S. market.
+0.50Proprietary product sales grew 48% quarter-over-quarter and 33% year-over-year, contributing to an improved gross margin of 57%. — Strong growth in high-margin proprietary products suggests an improving business model and a trajectory toward profitability.
+0.40MyMedi.ca experienced its first sequential quarterly revenue decline due to a 30% reduction in Veterans Affairs Canada (VAC) reimbursement rates. — Direct revenue loss from a key reimbursement channel creates a headwind for the company's digital health segment.
-0.30Which stocks this story touches
The company reported improved gross margins, strong growth in proprietary product sales, and progress toward profitability and new product launches.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.